Literature DB >> 28643126

Cancer Stem Cells in Hepatocellular Carcinoma.

Tamer Yagci1, Metin Cetin2, Pelin Balcik Ercin2.   

Abstract

BACKGROUND: Hepatocellular carcinoma is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Only a small proportion of patients benefit from curative treatment and the prognosis is very poor for the majority of cases due to late presentation, resistance to chemotherapy and high recurrence rate. In recent years, progress in stem cell biology allowed us to explain that hierarchically organized cancer stem cells (CSCs) drive histological and functional heterogeneity of hematological malignancies and solid tumors. METHODS AND
RESULTS: Also referred to as tumor-initiating cells, CSCs have been isolated from both hepatocellular carcinoma (HCC) cell lines and primary tumors by using hepatic progenitor markers. Although there is still no consensus on cancer stem cell phenotype in HCC, single or combined use of CSC markers defines a minor population of tumor cells with the capacity of self-renewing and the ability to recapitulate the original tumor heterogeneity.
CONCLUSIONS: This review focuses on the biological features of CSCs and their potential as diagnostic/prognostic tools and therapeutic targets in HCC.

Entities:  

Keywords:  Cancer stem cell markers; Cancer stem cells; Hepatocellular carcinoma; Metastasis; Tumor heterogeneity; Tumor recurrence

Year:  2017        PMID: 28643126     DOI: 10.1007/s12029-017-9960-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  58 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  CD44 is protective during hyperoxia-induced lung injury.

Authors:  Gerritje J W van der Windt; Marcel Schouten; Sacha Zeerleder; Sandrine Florquin; Tom van der Poll
Journal:  Am J Respir Cell Mol Biol       Date:  2010-05-12       Impact factor: 6.914

3.  CD13 is a therapeutic target in human liver cancer stem cells.

Authors:  Naotsugu Haraguchi; Hideshi Ishii; Koshi Mimori; Fumiaki Tanaka; Masahisa Ohkuma; Ho Min Kim; Hirofumi Akita; Daisuke Takiuchi; Hisanori Hatano; Hiroaki Nagano; Graham F Barnard; Yuichiro Doki; Masaki Mori
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

4.  Characterization of a side population of cancer cells from human gastrointestinal system.

Authors:  Naotsugu Haraguchi; Tohru Utsunomiya; Hiroshi Inoue; Fumiaki Tanaka; Koshi Mimori; Graham F Barnard; Masaki Mori
Journal:  Stem Cells       Date:  2005-10-20       Impact factor: 6.277

5.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells.

Authors:  Stephanie Ma; Kwok-Wah Chan; Liang Hu; Terence Kin-Wah Lee; Jana Yim-Hung Wo; Irene Oi-Lin Ng; Bo-Jian Zheng; Xin-Yuan Guan
Journal:  Gastroenterology       Date:  2007-04-15       Impact factor: 22.682

6.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.

Authors:  Zheng Zhu; Xiangfang Hao; Mingxia Yan; Ming Yao; Chao Ge; Jianren Gu; Jinjun Li
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

8.  Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.

Authors:  Taro Yamashita; Anuradha Budhu; Marshonna Forgues; Xin Wei Wang
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

9.  Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.

Authors:  Yi Tang; Krit Kitisin; Wilma Jogunoori; Cuiling Li; Chu-Xia Deng; Susette C Mueller; Habtom W Ressom; Asif Rashid; Aiwu Ruth He; Jonathan S Mendelson; John M Jessup; Kirti Shetty; Michael Zasloff; Bibhuti Mishra; E P Reddy; Lynt Johnson; Lopa Mishra
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-08       Impact factor: 11.205

10.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

View more
  4 in total

1.  Morphophenotypic Classification of Hepatocellular Carcinoma: the Biliary/Stem Cell Subgroup and Worst Outcome-Implications on Patient Selection.

Authors:  Rui Caetano Oliveira; Ricardo Martins; Ana Margarida Abrantes; Ângela Jesus; Paulo Teixeira; Carolina Canhoto; Pedro Guerreiro; Beatriz Costa; Mário Rui Silva; José Guilherme Tralhão; Maria Augusta Cipriano
Journal:  J Gastrointest Surg       Date:  2020-05-14       Impact factor: 3.452

Review 2.  Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.

Authors:  Javier A García-Vilas; Miguel Ángel Medina
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

Review 3.  SIRT1 in the Development and Treatment of Hepatocellular Carcinoma.

Authors:  Marius Farcas; Andrei-Alexandru Gavrea; Diana Gulei; Calin Ionescu; Alexandru Irimie; Cristina S Catana; Ioana Berindan-Neagoe
Journal:  Front Nutr       Date:  2019-09-25

4.  Cellular retinol binding protein-1 inhibits cancer stemness via upregulating WIF1 to suppress Wnt/β-catenin pathway in hepatocellular carcinoma.

Authors:  Xiangye Liu; Wenhua Shan; Tingting Li; Xiaoge Gao; Fanyun Kong; Hongjuan You; Delong Kong; Shuxi Qiao; Renxian Tang
Journal:  BMC Cancer       Date:  2021-11-14       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.